A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan

Clinical Cancer Research

Volumn 16, Issue 2, 2010, Pages 736-742

  Van Der Bol, Jessica M ^a   Mathijssen, Ron H J ^a   Creemers, Geert Jan M ^b   Planting, André S Th ^a   Loos, Walter J ^a   Wiemer, Erik A C ^a   Friberg, Lena E ^c   Verweij, Jaap ^a   Sparreboom, Alex ^a,d   De Jong, Floris A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c UPPSALA UNIVERSITY   (Sweden)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CYTOCHROME P450 3A4; GAMMA GLUTAMYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MIDAZOLAM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BODY HEIGHT; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CLASSIFICATION ALGORITHM; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG CLEARANCE; DRUG SAFETY; ENZYME ACTIVITY; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; GENOTYPE; HEAD AND NECK CANCER; HUMAN; JEJUNUM CANCER; LEUKOCYTE COUNT; LUNG SMALL CELL CANCER; MALE; MEDULLOBLASTOMA; MELANOMA; NEUTROPENIA; NEUTROPHIL COUNT; OVARY CARCINOMA; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SIDE EFFECT; SMOKING; STOMACH CANCER; UROGENITAL TRACT CANCER;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA; COLORECTAL NEOPLASMS; CYTOCHROME P-450 CYP3A; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; INDIVIDUALITY; INDIVIDUALIZED MEDICINE; MALE; MIDAZOLAM; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PHENOTYPE; PRODRUGS;

EID: 74549205743     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1526     Document Type: Article

References (33)

1. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
3. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
5. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27:2604-14.
6. Di Paolo A, Bocci G, Danesi R, et al. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol 2006;1:311-23.
7. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002;86:1297-302.
8. de Jong FA, Mathijssen RH, Xie R, et al. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004;10:4068-71.
9. Innocenti F, Janisch L, Das S, et al. A genotype-directed phase I study of irinotecan in advanced cancer patients. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. vol. 25, no. 18S (June 20 Supplement), 2007: Abstract 2502.
10. Falandry C, You B, Milano G, et al. Individual genotyping to optimize chemotherapy in metastatic colorectal cancer (MCRC): The COLOgen trial. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. vol. 25, no. 18S (June 20 supplement), 2007: Abstract 2510.
11. Hazama S, Nagashima A, Kondo H, et al. A genetic UGT1A1 polymorphism oriented phase I study of irinotecan (CPT-11) and doxifluridine (5′-DFUR: an intermediate form of capecitabine for metastatic colorectal cancer (MCRC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. vol. 24, no. 18S (June 20 supplement), 2006: Abstract 3602.
12. de Jong FA, Sparreboom A, Verweij J, Mathijssen RH. Lifestyle habits as a contributor to anti-cancer treatment failure. Eur J Cancer 2008;44:374-82.
13. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002;20:3122-9.
14. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-9.
15. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
16. Kharasch ED, Thummel KE, Watkins PB. CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assessCYP3Ainduction and inhibition. Mol Interv 2005;5:151-3.
17. Mathijssen RH, de Jong FA, van Schaik RH, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004;96:1585-92.
18. van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007;25:2719-26.
19. von Ahsen N, Oellerich M, Schutz E. DNA base bulge vs unmatched end formation in probe-based diagnostic insertion/deletion genotyping: genotyping the UGT1A1 (TA)(n) polymorphism by real-time fluorescence PCR. Clin Chem 2000;46:1939-45.
20. Sachs L. Applied statistics: a handbook of techniques. 2nd ed. New York: Springer-Verlag; 1984, p. 275
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinetic Biopharm 1981;9:503-12.
22. Ma JD, Nafziger AN, Rhodes G, et al. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol 2006;46:103-8.
23. Wong M, Balleine RL, Collins M, et al. CYP3A5 genotype and mid-azolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004;75:529-38.
24. Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008;4:108-13.
25. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucurono- syltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
26. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7.
27. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 2006;45:235-52.
28. Hooker AC, Ten Tije AJ, Carducci MA, et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther 2008;84:111-8.
29. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-53.
30. Li J, Karlsson MO, Brahmer J, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 2006;98:1714-23.
31. Yamamoto N, Tamura T, Murakami H, et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005;23:1061-9.
32. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 2008;84:704-9.
33. Mathijssen RH, Gurney H. Irinogenetics: how many stars are there in the sky? J Clin Oncol 2009;27:2578-9.